Oncology R&D spend has been the highest among all of the therapeutic areas for a good part of the last decade. As a result, we have seen the introduction of some ground-breaking therapies that have brought significant gains in cure and survival rates.

However, the net effect cost of cancer care is growing exponentially and is predicted to reach unsustainable levels. The focus is now on medical technologies and device innovations to bring much-needed evolution in the way new drugs are developed and the way patients are treated.

This seminar focuses on the medical device technologies and innovations with potential to bring grassroots changes in cancer research and the care delivery model. We will provide our perspective on how these change catalysts can impact patient experience, cost burdens and reimbursement models.

Media downloads

M1 Disruption of the care pathway in oncology.pdf
Harshal Shah
Head of Oncology Innovations, Global Medical Technology

Harshal is part of our global medical division based out of Boston, with more than a decade of experience in medical device development, product life cycle strategy, and innovation management. He has significant expertise in oncology patient journey, economics of cancer care and innovations in oncology. He has a Bachelor of Mechanical Engineering degree from Nirma Institute of Technology in India, an MBA from Syracuse University, New York, and he recently completed a post graduate program in cancer biology and therapeutics development from Harvard Medical School.